332 related articles for article (PubMed ID: 26255950)
1. Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review.
Joshi SR; Standl E; Tong N; Shah P; Kalra S; Rathod R
Expert Opin Pharmacother; 2015; 16(13):1959-81. PubMed ID: 26255950
[TBL] [Abstract][Full Text] [Related]
2. Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes.
Hedrington MS; Davis SN
Expert Opin Pharmacother; 2019 Dec; 20(18):2229-2235. PubMed ID: 31593486
[No Abstract] [Full Text] [Related]
3. Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; Rutten GE; Van Weel C
Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD003639. PubMed ID: 15846673
[TBL] [Abstract][Full Text] [Related]
4. Who should benefit from the use of alpha-glucosidase inhibitors?
Godbout A; Chiasson JL
Curr Diab Rep; 2007 Oct; 7(5):333-9. PubMed ID: 18173965
[TBL] [Abstract][Full Text] [Related]
5. Postprandial hyperglycemia in patients with type 2 diabetes mellitus.
Sudhir R; Mohan V
Treat Endocrinol; 2002; 1(2):105-16. PubMed ID: 15765626
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
7. Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation.
Standl E; Schnell O
Diab Vasc Dis Res; 2012 Jul; 9(3):163-9. PubMed ID: 22508699
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus].
Yamada K
Nihon Rinsho; 2003 Jul; 61(7):1219-23. PubMed ID: 12877088
[TBL] [Abstract][Full Text] [Related]
9. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis.
van de Laar FA; Lucassen PL; Akkermans RP; van de Lisdonk EH; Rutten GE; van Weel C
Diabetes Care; 2005 Jan; 28(1):154-63. PubMed ID: 15616251
[TBL] [Abstract][Full Text] [Related]
10. Switching α-glucosidase inhibitors to miglitol reduced glucose fluctuations and circulating cardiovascular disease risk factors in type 2 diabetic Japanese patients.
Hariya N; Mochizuki K; Inoue S; Saito M; Fuchigami M; Goda T; Osonoi T
Drugs R D; 2014 Sep; 14(3):177-84. PubMed ID: 25079671
[TBL] [Abstract][Full Text] [Related]
11. Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients.
Matsumura M; Monden T; Miyashita Y; Kawagoe Y; Shimizu H; Nakatani Y; Domeki N; Yanagi K; Ikeda S; Kasai K
Adv Ther; 2009 Jun; 26(6):660-6. PubMed ID: 19568704
[TBL] [Abstract][Full Text] [Related]
12. Drug therapy of postprandial hyperglycaemia.
Mooradian AD; Thurman JE
Drugs; 1999 Jan; 57(1):19-29. PubMed ID: 9951949
[TBL] [Abstract][Full Text] [Related]
13. Comparison of efficacies of a dipeptidyl peptidase IV inhibitor and alpha-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice.
Yamazaki K; Inoue T; Yasuda N; Sato Y; Nagakura T; Takenaka O; Clark R; Saeki T; Tanaka I
J Pharmacol Sci; 2007 May; 104(1):29-38. PubMed ID: 17485917
[TBL] [Abstract][Full Text] [Related]
14. Effect of two alpha-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms.
Fujisawa T; Ikegami H; Inoue K; Kawabata Y; Ogihara T
Metabolism; 2005 Mar; 54(3):387-90. PubMed ID: 15736118
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review.
Derosa G; Maffioli P
Clin Ther; 2012 Jun; 34(6):1221-36. PubMed ID: 22560622
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Cardiovascular Safety of Alpha Glucosidase Inhibitors.
Khwaja NUD; Arunagirinathan G
Curr Drug Saf; 2021; 16(2):122-128. PubMed ID: 33334296
[TBL] [Abstract][Full Text] [Related]
17. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
Derosa G; Franzetti I; Querci F; D'Angelo A; Maffioli P
Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
[TBL] [Abstract][Full Text] [Related]
18. Acarbose, an alpha-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation.
Azuma K; Toyofuku Y; Iesaki T; Otsuka A; Tanaka A; Mita T; Hirose T; Tanaka Y; Daida H; Kawamori R; Watada H
Biochem Biophys Res Commun; 2006 Jun; 345(2):688-93. PubMed ID: 16696939
[TBL] [Abstract][Full Text] [Related]
19. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.
Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; De Grauw WJ
Cochrane Database Syst Rev; 2006 Oct; (4):CD005061. PubMed ID: 17054235
[TBL] [Abstract][Full Text] [Related]
20. Alpha glucosidase inhibitors.
Kalra S
J Pak Med Assoc; 2014 Apr; 64(4):474-6. PubMed ID: 24864650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]